Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction
New England Journal of MedicinePublished 21 May 1998Open access
Tatjana Potpara
Citations1,322
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
When administered with heparin and aspirin, the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban was associated with a lower incidence of ischemic events in patients with acute coronary syndromes than in patients who received only hepar in and aspirin.
Abstract
When administered with heparin and aspirin, the platelet glycoprotein IIb/IIIa receptor inhibitor tirofiban was associated with a lower incidence of ischemic events in patients with acute coronary syndromes than in patients who received only heparin and aspirin.
Keywords
Medicine
New England Journal of MedicineThe Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
2,706 Citations1992Franklin H. Epstein, Valentı́n Fuster +3 more
The two hypotheses to explain the pathogenesis of atherosclerosis, the "incrustation" hypothesis and the "lipid" hypothesis, are now known.
New England Journal of MedicineUse of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
2,602 Citations1994The EPIC Investigators
Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
CirculationThrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
2,252 Citations1987James H. Chesebro, Genell L. Knatterud +8 more
In patients with acute myocardial infarction, rt-PA elicited reperfusion in twice as many occluded infarct-related arteries as compared with SK at each of seven serial observations during the first 90 min after onset of treatment.
New England Journal of MedicinePlatelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization
1,901 Citations1997The EPILOG Investigators
Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the riskof hemorrhage.
New England Journal of MedicineA Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease
1,432 Citations1997Marc J. Cohen, Christine Demers +11 more
Antithrombotic therapy with enoxaparin plus aspirin was more effective than unfractionated heparin plus aspirin in reducing the incidence of ischemic events in patients with unstable angina or non-Q-wave myocardial infarction in the early phase.
The LancetRandomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study
1,338 Citations1997CAPTURE, STGRP, non vooting member Tijssen, J.
In patients with refractory unstable angina, treatment with abciximab substantially reduces the rate of thrombotic complications, in particular myocardial infarction, before, during, and after PTCA.
New England Journal of MedicineAspirin, Heparin, or Both to Treat Acute Unstable Angina
1,278 Citations1988Pierre Théroux, Hélène Ouimet +11 more
It is concluded that in the acute phase of unstable angina, either aspirin or heparin treatment is associated with a reduced incidence of myocardial infarction, and there is a trend favoringHeparin over aspirin.
CirculationEffects of Platelet Glycoprotein IIb/IIIa Blockade With Tirofiban on Adverse Cardiac Events in Patients With Unstable Angina or Acute Myocardial Infarction Undergoing Coronary Angioplasty
948 Citations1997The RESTORE Investigators
In patients undergoing coronary angioplasty for acute coronary syndromes, tirofiban protects against early adverse cardiac events related to thrombotic closure.
The LancetRandomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
841 Citations1994Eric J. Topol, R.M. Califf +12 more
A monoclonal antibody Fab fragment directed against the platelet glycoprotein IIb/IIIa integrin, the receptor mediating the final common pathway of platelet aggregation, reduced the frequency of clinical restenosis in patients with unstable angina and carried a risk of bleeding complications.
New England Journal of MedicineA Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina
795 Citations1998The Platelet Receptor Inhibition in Ischemic Syndrome Management Study Investigators
Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed.
The LancetRisk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
780 Citations1990The RISC Group
Aspirin reduced event rate in non-Q-wave MI and unstable angina, independently of electrocardiographic abnormalities or concurrent drug therapy and Heparin had no significant influence on event rate, although the group treated with aspirin and heparin had the lowest number of events during the initial 5 days.
New England Journal of MedicinePlatelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
760 Citations1995Jeffrey Lefkovits, Edward F. Plow +1 more
Platelets have a key role in atherosclerosis, thrombosis, and acute coronary syndromes and therapeutic manipulation of platelet function has focused principally on the use of aspirin.
The LancetLow-molecular-weight heparin during instability in coronary artery disease
686 Citations1996Fragmin during Instability in Coronary Artery Disease (FRISC) study group
CirculationSpecific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications.
456 Citations1989James T. Willerson, Paolo Golino +3 more
It is believed that unstable angina and acute myocardial infarction are a continuum in relation to the process of coronary artery thrombosis and vasoconstriction.
CirculationAcute Coronary Syndromes
357 Citations1998Pierre Théroux, Valentı́n Fuster
Although non–Q-wave MI for many years was considered prognostically similar to unstable angina, recent longitudinal studies indicate that it is similar to Q-wave infarction2 3 (Fig 2⇓).
CirculationRandomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
245 Citations1994M. L. Simoons, M. J. de Boer +8 more
Combined therapy with c7E3 Fab, heparin, and aspirin appears safe and supports the concept that effective blockade of the platelet GPIIb/IIIa receptors can reduce myocardial infarction and facilitate PTCA in patients with refractory unstable angina.
CirculationPlatelet Membrane Receptor Glycoprotein IIb/IIIa Antagonism in Unstable Angina
181 Citations1996Pierre Roux, Simon Kouz +13 more
The nonpeptide GP IIb/IIIa antagonist lamifiban protected patients with unstable angina from severe ischemic events during a 3- to 5-day infusion and reduced the incidence of death and infarction at 1 month, suggesting considerable promise for this new therapeutic approach.
Journal of Medicinal ChemistryNon-Peptide Fibrinogen Receptor Antagonists. 2. Optimization of a Tyrosine Template as a Mimic for Arg-Gly-Asp
178 Citations1994Melissa S. Egbertson, C. T.‐C. CHANG +7 more
Compound 23m inhibited in vitro platelet aggregation with an IC50 of 9 nM and demonstrated a selectivity of > 24,000-fold between platelet and human umbilical vein endothelial cell fibrinogen receptors, suggesting that 23m may be useful in the treatment of arterial occlusive disorders.
CirculationMK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man.
164 Citations1993Kathelijne Peerlinck, Inge De Lepeleire +8 more
The results from this study indicate that MK-383 appears to be well tolerated and active in man and is the first nonpeptide GPIIb/IIMa antagonist that can be used to investigate the antithrombotic potential of this new class of antiplatelet agents.
CirculationEffects of Integrelin, a Platelet Glycoprotein IIb/IIIa Receptor Antagonist, in Unstable Angina
109 Citations1996Steven P. Schulman, Pascal J. Goldschmidt‐Clermont +26 more
Intravenous Integrelin is well tolerated, is a potent reversible inhibitor of platelet aggregation, and added to full-dose heparin reduces the number and duration of Holter ischemic events in patients with unstable angina compared with aspirin.
The American Journal of CardiologyA new clinical classification for hospital prognosis of unstable angina pectoris
56 Citations1995David G. Rizik, Shaun Healy +7 more
This easily deduced, universally applicable categorization of unstable angina is highly prognostic of in-hospital adverse cardiac events and hence could have potential use for triage decisions regarding hospital admission and intensity of therapy.